Moderna publishes Q3 2026 earnings call transcript
MRNA•Moderna raised its full-year revenue growth guidance to 15%-25% from up to 10% after third-quarter revenue rose 29% to $1.3 billion. Net income was $162 million, and the company lowered its full-year R&D expense guidance by $200 million to $2.7 billion.
1. Revenue and expenses
Moderna reported third-quarter revenue of $1.3 billion, up 29%, and net income of $162 million, compared with a loss a year earlier. CFO Jamey Mock raised full-year revenue growth guidance to 15%-25% from up to 10% and lowered full-year R&D expense guidance by $200 million to $2.7 billion.
2. Pipeline updates
Management said intismeran reduced the risk of melanoma recurrence or death by 42% in Phase III and that it targets a regulatory submission this year with Merck. The company halted plans for another norovirus trial cohort after an interim analysis did not meet the criteria for early success, pending discussions with regulators.




